跳至主要内容
临床试验/ACTRN12623001236684
ACTRN12623001236684尚未招募3 期

A parallel group superiority trial comparing the impacts of Tirzepatide, and the combination of Tirzepatide and Resistance Exercise training (T-REX), on body composition and cardiovascular variables, in community dwelling men and post-menopausal women with overweight and obesity

The University of Western Australia0 个研究点目标入组 120 人开始时间: 2023年11月30日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 70 Years(—)
性别
All

入选标准

  • Men and women aged 50-70 years with body mass index (BMI) greater than or equal to 30 kg/m², or greater than or equal to 27 kg/m² with at least one weight-related comorbidity (e.g. hypertension, dyslipidaemia or obstructive sleep apnoea)

排除标准

  • Known pregnancy, cardiovascular disease, diabetes, any history of pancreatitis; any history of multiple endocrine neoplasia (MEN) type 2 or medullary thyroid carcinoma; previous or planned bariatric surgery; any prior use of incretin-based therapies; use of non-incretin based anti-obesity or CV medications (e.g. statins, BP drugs) within 3 months of enrolment; and any other clinically significant illnesses (e.g. cancer, severe respiratory disease). Total cholesterol greater than 7.0 mmol/L, LDL greater than 4.0 mmol/L, eGFR less than 45 mL/min, HbA1c greater than 7.0% and/or evidence of significant liver disease. BP greater than 160/100 mmHg during the clinic visit.

研究者

相似试验

The Combination of Tirzepatide and Resistance... | 临床试验